Please login to the form below

Not currently logged in
Email:
Password:

Srdjan Stankovic joins Acadia Pharmaceuticals

He moves to the San Diego biopharma from Alkermes

San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development.

He joins the firm from Alkermes, where he most recently served as senior vice president of clinical development and medical affairs from 2013 to 2015.

Prior to this he worked at Teva as senior vice president and head of global clinical development following that company's acquisition of Cephalon, where he was senior vice president, worldwide clinical research. 

Stankovic has also held executive positions in research and development at Forest Laboratories, Neurogen, Johnson and Johnson and UCB.

Steve Davis, Acadia's president and chief executive officer, said: “Serge has a track record of transforming promising research into important medicines that address unmet needs of patients.

"We look forward to his contributions as we advance Nuplazid through NDA review for Parkinson's disease psychosis, prepare for the planned commercialisation of Nuplazid in the US  and continue our efforts to explore the full potential of Nuplazid to treat patients suffering from additional CNS disorders.” 

Nuplazid (pimavanserin), Acadia's lead candidate, has been submitted to the US FDA for a licence to treat Parkinson's disease psychosis, a condition that currently has no approved treatment.

Stankovic said: “There is a strong need for continued innovation in the treatment of CNS disorders such as Parkinson's disease, Alzheimer's disease, and schizophrenia. Acadia is at the forefront in developing groundbreaking medicines to treat debilitating symptoms associated with these diseases.

"I look forward to leading the team in advancing the promising development programmes with Nuplazid."

11th January 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...

Infographics